

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

Cost-comparison - Somapacitan for treating growth hormone deficiency in people 3 to 17 years [ID6178]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

- | | |
|---|--|
| 1. | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| It was noted during scoping that growth hormone deficiency disproportionately impacts boys. Additionally, it was noted that socioeconomic status negatively impacts adherence to therapy. | |
| Issues related to differences in prevalence or incidence of a disease cannot typically be addressed in a technology appraisal. | |

- | | |
|--|---|
| 2. | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| The EAG noted that weekly dose regimens may help ensure treatments for children and young people with a phobia against injections (as they require fewer injections per week) or with other circumstances making daily administration difficult. | |

- | | |
|----|---|
| 3. | Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|----|---|

No additional issues

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

No. The appraisal is a cost comparison so the final draft guidance includes only a brief overview of why these recommendations were made.

Approved by Associate Director (name): Ian Watson

Date: 8 April 2025